Previous studies found that Cyr61 was upregulated in the serum of certain cancers and associated with poor prognosis, such as breast cancer [18], gastric cancer [19], hepatocellular carcinoma [20], and CRC [21]. This evidence concerns the gene CCN1 and cancer.